If GIPR agonism induced by tirzepatide treatment is responsible for enhanced ß-cell secretion, it is reasonable to assume a time-dependent process re-establishing GIP as an effective insulin secretagogue even in advanced type 2 diabetes. Here, GIP is linked to type 2 diabetes mellitus.